

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 September 2003 (18.09.2003)

PCT

(10) International Publication Number  
**WO 03/075911 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/216**,  
31/192, A61P 9/00, 13/00

(21) International Application Number: PCT/CA03/00335

(22) International Filing Date: 11 March 2003 (11.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/362,243 11 March 2002 (11.03.2002) US

(71) Applicants and

(72) Inventors: **ZAHRAKKA, Peter**, [CA/CA]; 351 Tache Avenue, Winnipeg, Manitoba R2H 2A6 (CA). **TAYLOR,, Carla** [CA/CA]; 351 Tache Avenue, Winnipeg, Manitoba R2H 2A6 (CA).

(74) Agent: **ADE & COMPANY**; 1700-360 Main Street, Winnipeg, Manitoba R3C 3Z3 (CA).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: USE OF PPAR ALPHA AGONISTS FOR THE TREATMENT OF VASCULAR AND RENAL DISEASES

(57) Abstract: Activation of peroxisome proliferator activated receptor alpha (PPAR $\alpha$ ) by administration of therapeutic amounts of a PPAR $\alpha$  agonist, WY-14643, inhibits the proliferation of vascular smooth muscle cells, hepatoma cells and human renal proximal tubule cells. WY-14643 may be applicable as a medicament for the treatment of proliferative vascular disease (atherosclerosis, hypertension), revascularization-induced injury (restenosis) and chronic renal failure.

WO 03/075911 A1

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/ 03/00335

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7 A61K31/216 A61K31/192 A61P9/00 A61P13/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, MEDLINE, WPI Data, EMBASE, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 156 003 A (METZ GUNTER ET AL) 22 May 1979 (1979-05-22) the whole document ---	1-6
X	US 4 250 191 A (EDWARDS K DAVID) 10 February 1981 (1981-02-10) abstract column 1, line 1 - line 2 column 1, line 16 - line 21 column 1, line 41 - line 50 column 2, line 18 - line 64 ---	1-6
X	US 4 976 970 A (LANDY WADY N) 11 December 1990 (1990-12-11) the whole document --- -/--	1-6



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

15 July 2003

Date of mailing of the international search report

06/08/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Giacobbe, S

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 593 971 A (TSCHOLLAR WERNER ET AL) 14 January 1997 (1997-01-14) claims 1,2 ---	1-6
X	WO 98 05331 A (LIGAND PHARM INC) 12 February 1998 (1998-02-12) page 5, line 11 - line 16 page 3, line 18 - line 24 claims 14,18,22-25 ---	1-6
X	US 5 880 148 A (EDGAR ALAN DUNLAP ET AL) 9 March 1999 (1999-03-09) claims 1,9 ---	1-6
X	WO 01 27128 A (SQUIBB BRISTOL MYERS CO ;SHER PHILIP M (US); WU GANG (US); ELLSWOR) 19 April 2001 (2001-04-19) claims 16,23,24,26 ---	1-6
X	WO 01 60807 A (JONES A BRIAN ;LIU KUN (US); XU LIBO (US); MERCK & CO INC (US)) 23 August 2001 (2001-08-23) claim 25 ---	1-6
X	WO 02 09682 A (ARDUINI ARDUINO ;SIGMA TAU IND FARMACEUTI (IT)) 7 February 2002 (2002-02-07) page 4, line 14 - line 21 page 5, paragraph 1 claims 1,3 ---	1-6
Y	NEVE B P FRUCHART J-C STAELS B: "Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis" BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 60, 2000, pages 1245-1250, XP002954394 ISSN: 0006-2952 abstract ---	1-6
Y	TANAKA TAKUJI ET AL: "Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats." CANCER RESEARCH, vol. 61, no. 6, 15 March 2001 (2001-03-15), pages 2424-2428, XP002247794 ISSN: 0008-5472 abstract ---	1-6

-/--

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	HAMANO T ET AL: "Peroxisome proliferator-activated receptor alpha (PPAR alpha) agonist, WY-14,643, increased transcription of myosin light chain-2 in cardiomyocytes." THE JOURNAL OF TOXICOLOGICAL SCIENCES. JAPAN DEC 2001, vol. 26, no. 5, December 2001 (2001-12), pages 275-284, XP009013868 ISSN: 0388-1350 abstract	1-6
X	--- HORNING DANIELA ET AL: "Nuclear peroxisome proliferator-activated receptors alpha and gamma have opposing effects on monocyte chemotaxis in endometriosis." JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 86, no. 7, July 2001 (2001-07), pages 3108-3114, XP002247795 ISSN: 0021-972X abstract	4,6
P,X	--- WO 02 34259 A (PLAYFORD DAVID ;WATTS GERALD (AU); FOURNIER LAB IRELAND LTD (IE)) 2 May 2002 (2002-05-02) the whole document -----	1-6

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA 03/00335

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 3 and 4 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

Indicates patent family members

International Application No

PCT/03/00335

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4156003	A	22-05-1979	BE 870314 A1	02-01-1979
US 4250191	A	10-02-1981	US 4472410 A US 4361564 A	18-09-1984 30-11-1982
US 4976970	A	11-12-1990	MX 9203208 A1	01-07-1992
US 5593971	A	14-01-1997	US 5461039 A US 5298497 A	24-10-1995 29-03-1994
WO 9805331	A	12-02-1998	AU 4050797 A EP 0930882 A2 WO 9805331 A2	25-02-1998 28-07-1999 12-02-1998
US 5880148	A	09-03-1999	FR 2730231 A1 AT 194078 T DE 69608974 D1 DE 69608974 T2 DK 724877 T3 EP 0724877 A1 ES 2148694 T3 GR 3034147 T3 JP 8253416 A PT 724877 T	09-08-1996 15-07-2000 03-08-2000 08-02-2001 16-10-2000 07-08-1996 16-10-2000 30-11-2000 01-10-1996 29-12-2000
WO 0127128	A	19-04-2001	AU 7848300 A BR 0014722 A CA 2388818 A1 CN 1407990 T CZ 20021285 A3 EP 1224195 A1 JP 2003511458 T NO 20021721 A TR 200200986 T2 WO 0127128 A1 US 2002137903 A1 US 6414126 B1	23-04-2001 25-02-2003 19-04-2001 02-04-2003 12-02-2003 24-07-2002 25-03-2003 10-06-2002 22-07-2002 19-04-2001 26-09-2002 02-07-2002
WO 0160807	A	23-08-2001	AU 3821401 A CA 2400021 A1 EP 1259494 A1 WO 0160807 A1 US 2002173663 A1	27-08-2001 23-08-2001 27-11-2002 23-08-2001 21-11-2002
WO 0209682	A	07-02-2002	IT RM20000433 A1 AU 7768601 A BR 0112874 A CA 2415042 A1 EP 1305020 A2 WO 0209682 A2	01-02-2002 13-02-2002 01-07-2003 07-02-2002 02-05-2003 07-02-2002
WO 0234259	A	02-05-2002	AU 2176502 A EE 200300165 A WO 0234259 A1	06-05-2002 16-06-2003 02-05-2002